GABRD could serve as a biomarker for HCC stage-IV [38]; SET And MYND Domain Containing 3 (SMYD3) promoted the tumorigenicity and intrahepatic metastasis of HCC cells, and could be a practical prognosis marker or therapeutic target against HCC [39]. Here, SMYD3 is linked to hepatocellular carcinoma.